Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
| | | | | |

Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products

On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 millionin contract modifications from the…

U.S. FDA Approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
| | | |

U.S. FDA Approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE™ (Pneumococcal…